🏛️ Verified NIH Record • Updated 2026-08-25

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) (NCT06170788)

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Merck Sharp & Dohme LLC

🩺 Plain-English Summary (8th-Grade Level)

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (24 items).

Location: Mayo Clinic in Arizona - Phoenix ( Site 0147) — Phoenix, Arizona

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements.
  • Has Grade ≥2 peripheral neuropathy.
  • History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
  • Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea).
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease within the 6 months preceding study intervention.
  • Received prior systemic anticancer therapy for their metastatic NSCLC.
  • Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor Note: Prior treatment with an anti-PD-1, anti-PD- L1, or anti-PD-L2 agent in the neoadjuvant or adjuvant setting for nonmetastatic resectable NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC.
  • Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.
  • Received radiation therapy to the lung that is \>30 Gy within 6 months of start of study intervention.
  • Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.
  • Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (220 Sites)

  • Mayo Clinic in Arizona - Phoenix ( Site 0147) — Phoenix, Arizona
  • Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0130) — Burbank, California
  • Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0132) — Grand Junction, Colorado
  • Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0133) — Jacksonville, Florida
  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0106) — Marietta, Georgia
  • The University of Louisville, James Graham Brown Cancer Center ( Site 0121) — Louisville, Kentucky
  • New England Cancer Specialists ( Site 0143) — Westbrook, Maine
  • University of Massachusetts Chan Medical School-Division of Hematology/Oncology ( Site 0144) — Worcester, Massachusetts
  • Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0115) — Minneapolis, Minnesota
  • Mayo Clinic - Rochester ( Site 0148) — Rochester, Minnesota
  • Hattiesburg Clinic Hematology/Oncology ( Site 0104) — Hattiesburg, Mississippi
  • Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0134) — Reno, Nevada
  • University Hospitals Cleveland Medical Center ( Site 0119) — Cleveland, Ohio
  • Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0117) — Corvallis, Oregon
  • Oncology Consultants P.A. ( Site 0129) — Houston, Texas
  • Instituto Alexander Fleming ( Site 0306) — Ciudad Autónoma de Buenos Aires, Buenos Aires
  • Hospital Británico de Buenos Aires-Oncology ( Site 0304) — Buenos Aires, Buenos Aires F.D.
  • Centro Privado de RMI Río Cuarto S.A. II ( Site 0310) — Río Cuarto, Córdoba Province
  • Instituto de Oncología de Rosario ( Site 0301) — Rosario, Santa Fe Province
  • Hospital Aleman-Oncology ( Site 0300) — Buenos Aires,
  • Port Macquarie - Mid North Coast Cancer Institute-Medical Oncology ( Site 3002) — Port Macquarie, New South Wales
  • Westmead Hospital ( Site 3000) — Westmead, New South Wales
  • Grampians Health-Medical Oncology ( Site 3001) — Ballarat Central, Victoria
  • Northern Hospital ( Site 3003) — Epping, Victoria
  • Peninsula University Hospital ( Site 3004) — Frankston, Victoria

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗